Abstract
In the past few years accumulating evidence involved chromosomal instability and the subsequent aneuploidy that it generates in tumor formation. Moreover, the misregulation of most of the proteins involved in the mitotic checkpoint as well as kinetochore assembly has proven to have tumorigenic potential in vivo. Thus, the overexpression of Ndc80/Hec1, an outer kinetochore protein involved in spindle assembly checkpoint (SAC) recruitment, has been shown to induce tumor formation in different organs. Since Ndc80/Hec1 is a protein “ highly expressed in cancer” , it is an attractive target that can be used for cancer therapy. In this direction, several strategies aiming to in vivo block this complex structure and activity are being developed, and some of them have demonstrated to have tumor growth inhibition potential. These therapies represent a potential interesting approach for the treatment of malignancies where Ndc80/Hec1 expression is upregulated. Here we will discuss different aspects of Ndc80/Hec1 biology, its role in kinetochore assembly and spindle checkpoint, and its importance as a potential therapeutical target.
Keywords: Ndc80, Hec1, Kinetochores, spindle checkpoint, aneuploidy, cancer
Current Drug Therapy
Title: Targeting the Kinetochore in Cancer Therapy: The Ndc80/Hec1 Complex
Volume: 5 Issue: 1
Author(s): Elena Diaz-Rodriguez
Affiliation:
Keywords: Ndc80, Hec1, Kinetochores, spindle checkpoint, aneuploidy, cancer
Abstract: In the past few years accumulating evidence involved chromosomal instability and the subsequent aneuploidy that it generates in tumor formation. Moreover, the misregulation of most of the proteins involved in the mitotic checkpoint as well as kinetochore assembly has proven to have tumorigenic potential in vivo. Thus, the overexpression of Ndc80/Hec1, an outer kinetochore protein involved in spindle assembly checkpoint (SAC) recruitment, has been shown to induce tumor formation in different organs. Since Ndc80/Hec1 is a protein “ highly expressed in cancer” , it is an attractive target that can be used for cancer therapy. In this direction, several strategies aiming to in vivo block this complex structure and activity are being developed, and some of them have demonstrated to have tumor growth inhibition potential. These therapies represent a potential interesting approach for the treatment of malignancies where Ndc80/Hec1 expression is upregulated. Here we will discuss different aspects of Ndc80/Hec1 biology, its role in kinetochore assembly and spindle checkpoint, and its importance as a potential therapeutical target.
Export Options
About this article
Cite this article as:
Diaz-Rodriguez Elena, Targeting the Kinetochore in Cancer Therapy: The Ndc80/Hec1 Complex, Current Drug Therapy 2010; 5 (1) . https://dx.doi.org/10.2174/1574885511005010029
DOI https://dx.doi.org/10.2174/1574885511005010029 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Prostate Cancer Molecular Background: The IGF-1Ec Story
Clinical Cancer Drugs Sorbinil, an Aldose Reductase Inhibitor, in Fighting Against Diabetic Complications
Medicinal Chemistry The Complex Biology of FOXO
Current Drug Targets Silimarin and Cancer
Anti-Cancer Agents in Medicinal Chemistry Perspectives of Protein Kinase C (PKC) Inhibitors as Anti-Cancer Agents
Mini-Reviews in Medicinal Chemistry Stem Cells as Vectors to Deliver HSV/tk Gene Therapy for Malignant Gliomas
Current Stem Cell Research & Therapy The Human Glioma-Associated Oncogene Homolog 1 (GLI1) Family of Transcription Factors in Gene Regulation and Diseases
Current Genomics The Polyhedric Abl Kinases and their Pharmacologic Inhibitors
Current Enzyme Inhibition An Update on MDMX and Dual MDM2/X Inhibitors
Current Topics in Medicinal Chemistry Recent Advances in the Development of Selective Small Molecule Inhibitors for Cyclin-Dependent Kinases
Current Topics in Medicinal Chemistry Four Major Factors Regulate Phosphatidylinositol 3-kinase Signaling Pathway in Cancers Induced by Infection of Human Papillomaviruses
Current Medicinal Chemistry Historical Spice as a Future Drug: Therapeutic Potential of Piperlongumine
Current Pharmaceutical Design Advances in the Pharmacologic Treatment of Hepatocellular Carcinoma
Current Clinical Pharmacology Towards Cure of CML: Why We Need to Know More About CML Stem Cells?
Current Stem Cell Research & Therapy Could Growth Factor-Mediated Extracellular Matrix Deposition and Degradation Offer the Ground for Directed Pharmacological Targeting in Fibrosarcoma?
Current Medicinal Chemistry Cell Cycle Regulatory Kinase Modulators: Interim Progress and Issues
Current Topics in Medicinal Chemistry Pioglitazone and Cancer: Angel or Demon?
Current Pharmaceutical Design From Dual Peroxisome Proliferator Activated Receptor Agonists to Selective Peroxisome Proliferator Activated Receptor Modulators
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Atoh1: Landscape for Inner Ear Cell Regeneration
Current Gene Therapy Subject Index To Volume 8
Current Pharmaceutical Design